476 related articles for article (PubMed ID: 33008960)
1. Review on therapeutic targets for COVID-19: insights from cytokine storm.
Mélo Silva Júnior ML; Souza LMA; Dutra REMC; Valente RGM; Melo TS
Postgrad Med J; 2021 Jun; 97(1148):391-398. PubMed ID: 33008960
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.
Roshanravan N; Seif F; Ostadrahimi A; Pouraghaei M; Ghaffari S
Arch Med Res; 2020 Oct; 51(7):608-612. PubMed ID: 32682575
[TBL] [Abstract][Full Text] [Related]
4. The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.
Wulandari S; Hartono ; Wibawa T
Immunology; 2023 Jun; 169(2):117-131. PubMed ID: 36571562
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
7. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!
Coperchini F; Chiovato L; Rotondi M
Front Immunol; 2021; 12():668507. PubMed ID: 33981314
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
10. Cytokine storm syndrome in coronavirus disease 2019: A narrative review.
Gao YM; Xu G; Wang B; Liu BC
J Intern Med; 2021 Feb; 289(2):147-161. PubMed ID: 32696489
[TBL] [Abstract][Full Text] [Related]
11. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.
Peng X; Wang Y; Xi X; Jia Y; Tian J; Yu B; Tian J
Cardiovasc Drugs Ther; 2021 Apr; 35(2):231-247. PubMed ID: 33404925
[TBL] [Abstract][Full Text] [Related]
12. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
13. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
Pinheiro MM; Fabbri A; Infante M
Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
[TBL] [Abstract][Full Text] [Related]
15. The cytokine storm and COVID-19.
Hu B; Huang S; Yin L
J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
[TBL] [Abstract][Full Text] [Related]
16. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J; Jiang M; Chen X; Montaner LJ
J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
[TBL] [Abstract][Full Text] [Related]
17. Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19.
Fouladseresht H; Doroudchi M; Rokhtabnak N; Abdolrahimzadehfard H; Roudgari A; Sabetian G; Paydar S
Cytokine Growth Factor Rev; 2021 Apr; 58():32-48. PubMed ID: 33199179
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Mendoza-Pinto C; García-Carrasco M; Munguía Realpozo P; Méndez-Martínez S
Reumatol Clin (Engl Ed); 2021 Oct; 17(8):431-436. PubMed ID: 34625144
[TBL] [Abstract][Full Text] [Related]
20. Molecular Insights into Severe Acute Respiratory Syndrome Coronavirus 2 Pathobiology: Dissecting the Interplay between Cellular Innate Immunity and Immune Evasion.
Maciorowski D; Mohama S; Alsawi MA; Ilc DJ; Gupta Y; El Idrissi S; Lodolce JP; Kempaiah P
Crit Rev Immunol; 2020; 40(6):485-496. PubMed ID: 33900693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
